# Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)

Source: https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/  
OnCo record `gallbladder-cancer-in-biliary-trials` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Almost every drug trial for gallbladder cancer also enrols bile duct cancers, so the evidence comes from mixed groups in which gallbladder cancer is usually a fifth to a half of patients. This entry lists the trials open to people with gallbladder cancer and what each reported for the gallbladder subgroup.

## Summary

Gallbladder cancer is rarely trialled on its own. In the landmark trials it was one stratum among three: 25 percent of TOPAZ-1 patients had gallbladder cancer (FDA label), KEYNOTE-966 stratified randomisation by site of origin including gallbladder, ABC-06 enrolled gallbladder and ampullary cancer alongside cholangiocarcinoma, SWOG S1815 had 16 percent gallbladder cancer and BILCAP required muscle-invasive gallbladder cancer for entry. HER2 trials are the exception where gallbladder cancer dominates: 53 percent of HERIZON-BTC-01 patients had gallbladder cancer. Subgroup results are sparse and exploratory: in S1815 the triplet improved progression-free but not overall survival more in gallbladder cancer than in cholangiocarcinoma (interaction p 0.01 and 0.28), and in TreeTopp varlitinib gave a non-significant progression-free survival signal in gallbladder cancer (2.9 versus 1.6 months, hazard ratio 0.55, confidence interval crossing 1). Gallbladder-only randomised trials exist mainly in India (POLCAGB, RUGB, NEOGB) and the United States (OPT-IN) and address surgery, radiotherapy and neoadjuvant timing rather than new drugs. The trials linked here are every interventional phase 2 or 3 study on ClinicalTrials.gov or ISRCTN that was open or active in September 2026 and names gallbladder cancer in its conditions or eligibility, with UK sites quoted where the registry lists them.

## Fields

- Kind: Term
- Last checked: 2026-09-24
- Also known as: Gallbladder subgroup; Biliary tract cancer trial eligibility

## Sources

- Imfinzi label (openFDA): TOPAZ-1 primary tumour location ICCA 56%, ECCA 18%, GBC 25%: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22IMFINZI%22
- Ziihera label (openFDA): 53% gallbladder cancer in HERIZON-BTC-01: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ZIIHERA%22
- SWOG S1815 (JCO 2025): 16% gallbladder cancer, subgroup interaction tests: https://doi.org/10.1200/JCO-24-01383
- TreeTopp (ESMO Open 2022): gallbladder subgroup: https://doi.org/10.1016/j.esmoop.2021.100314

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- terms: [Intrahepatic, perihilar, distal and gallbladder cancer](https://onco.cc/terms/biliary-anatomy-subtypes/)
- trials: [A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct07632235/), [A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.](https://onco.cc/trials/nct07729033/), [A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.](https://onco.cc/trials/nct07679399/), [A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.](https://onco.cc/trials/nct07623642/), [A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement](https://onco.cc/trials/nct06728410/), [A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers](https://onco.cc/trials/nct07351591/), [A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07269158/), [A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)](https://onco.cc/trials/nct07471165/), [A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen](https://onco.cc/trials/nct07099794/), [A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs](https://onco.cc/trials/nct06423170/), [A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer](https://onco.cc/trials/nct07135544/), [A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.](https://onco.cc/trials/nct06654947/), [A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)](https://onco.cc/trials/nct05849480/), [A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer](https://onco.cc/trials/nct02151084/), [A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.](https://onco.cc/trials/nct06620848/), [A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer](https://onco.cc/trials/nct02632305/), [ABC-02](https://onco.cc/trials/abc-02/), [ABC-06](https://onco.cc/trials/abc-06/), [ABC-07](https://onco.cc/trials/abc-07/), [ABC-12](https://onco.cc/trials/abc-12/), [ACTICCA-1](https://onco.cc/trials/acticca-1/), [Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07392541/), [Adebrelimab Plus S-1 for Resected Cholangiocarcinoma](https://onco.cc/trials/nct07561775/), [Adjuvant Chemotherapy for BTC Based on 3D-PTA](https://onco.cc/trials/nct07296666/), [Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers](https://onco.cc/trials/nct03801083/), [Agnostic Therapy in Rare Solid Tumors](https://onco.cc/trials/nct06638931/), [AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer](https://onco.cc/trials/nct07767994/), [Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma](https://onco.cc/trials/nct07780838/), [Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer](https://onco.cc/trials/nct07569679/), [An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.](https://onco.cc/trials/nct07282262/), [An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies](https://onco.cc/trials/nct07668453/), [Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment](https://onco.cc/trials/nct06662877/), [Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07635290/), [ASCOT (JCOG1202)](https://onco.cc/trials/ascot-jcog1202/), [Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types](https://onco.cc/trials/nct05000294/), [Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II](https://onco.cc/trials/nct07649980/), [BILCAP](https://onco.cc/trials/bilcap/), [BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion](https://onco.cc/trials/nct07594626/), [Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma](https://onco.cc/trials/nct06438822/), [Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct06901622/), [Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer](https://onco.cc/trials/nct05451290/), [Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody](https://onco.cc/trials/nct05994001/), [Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer](https://onco.cc/trials/nct06280508/), [Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC](https://onco.cc/trials/nct06037655/), [Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct07570849/), [CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence](https://onco.cc/trials/nct06037980/), [Combination Immunotherapy in Rare Cancers Under InvesTigation](https://onco.cc/trials/nct04969887/), [Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer](https://onco.cc/trials/nct05757336/), [Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07151872/), [Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma](https://onco.cc/trials/nct03937830/), [ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations](https://onco.cc/trials/combomatch-binimetinib-folfox/), [Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)](https://onco.cc/trials/nct06502080/), [CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors](https://onco.cc/trials/nct05733000/), [Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.](https://onco.cc/trials/nct07829874/), [CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers](https://onco.cc/trials/nct06548412/), [DEBATE](https://onco.cc/trials/debate/), [DESTINY-PanTumor02](https://onco.cc/trials/destiny-pantumor02/), [DETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers](https://onco.cc/trials/determine-arm04/), [Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07159217/), [Domvanalimab and Zimberelimab in Advanced Liver Cancers](https://onco.cc/trials/nct05724563/), [Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer](https://onco.cc/trials/nct03482102/), [Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)](https://onco.cc/trials/nct05451043/), [Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer](https://onco.cc/trials/nct05640791/), [Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC](https://onco.cc/trials/nct06490107/), [EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer](https://onco.cc/trials/ea2197-ivonescimab/), [Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study](https://onco.cc/trials/nct07636824/), [Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer](https://onco.cc/trials/nct07638501/), [Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07003815/), [EORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer](https://onco.cc/trials/eortc-1607-pembro-cisgem/), [Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers](https://onco.cc/trials/nct04645160/), [Evaluating Novel Therapies in ctDNA Positive GI Cancers](https://onco.cc/trials/nct05482516/), [Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor](https://onco.cc/trials/nct07631884/), [Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma](https://onco.cc/trials/nct07105852/), [FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers](https://onco.cc/trials/nct07478523/), [First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)](https://onco.cc/trials/nct05749900/), [GAIN (AIO/CALGP/ACO)](https://onco.cc/trials/gain-igbc/), [Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)](https://onco.cc/trials/nct06963060/), [Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer](https://onco.cc/trials/nct07310069/), [Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer](https://onco.cc/trials/nct06591650/), [Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies](https://onco.cc/trials/nct07599995/), [Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)](https://onco.cc/trials/gap-phase2-mdacc/), [Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)](https://onco.cc/trials/nct07433673/), [HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06389500/), [Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07636798/), [Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma](https://onco.cc/trials/nct03364530/), [HERIZON-BTC-01](https://onco.cc/trials/herizon-btc-01/), [HERIZON-BTC-302](https://onco.cc/trials/herizon-btc-302/), [Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)](https://onco.cc/trials/nct04238637/), [Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer](https://onco.cc/trials/nct07745296/), [Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer](https://onco.cc/trials/nct07263360/), [Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies](https://onco.cc/trials/nct06993025/), [KEYNOTE-158](https://onco.cc/trials/keynote-158/), [KEYNOTE-966](https://onco.cc/trials/keynote-966/), [KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma](https://onco.cc/trials/nct05985707/), [Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment](https://onco.cc/trials/nct05170438/), [Ligufalimab and Cadonilimab in Advanced Liver Cancers](https://onco.cc/trials/nct06789848/), [Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07797816/), [mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line](https://onco.cc/trials/nct07062536/), [MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma](https://onco.cc/trials/nct07036380/), [Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers](https://onco.cc/trials/nct04910386/), [MyPathway](https://onco.cc/trials/mypathway/), [NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer](https://onco.cc/trials/nct04005339/), [Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma](https://onco.cc/trials/nct06903273/), [NEOGB](https://onco.cc/trials/neogb/), [NIFE (AIO-YMO HEP-0315)](https://onco.cc/trials/nife/), [NIFTY](https://onco.cc/trials/nifty/), [Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer](https://onco.cc/trials/nct05705492/), [Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations](https://onco.cc/trials/nct04042831/), [Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy](https://onco.cc/trials/nct05222971/), [Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)](https://onco.cc/trials/nct06919848/), [OPT-IN (EA2197)](https://onco.cc/trials/opt-in/), [PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment](https://onco.cc/trials/nct04634058/), [Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06230471/), [Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma](https://onco.cc/trials/nct06530823/), [Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma](https://onco.cc/trials/nct07786766/), [Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers](https://onco.cc/trials/nct06001658/), [Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer](https://onco.cc/trials/nct07793253/), [Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer](https://onco.cc/trials/nct06852287/), [Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06708858/), [Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct07530445/), [Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer](https://onco.cc/trials/nct07670273/), [Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer](https://onco.cc/trials/nct07704177/), [POLCAGB](https://onco.cc/trials/polcagb/), [Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07159204/), [Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study](https://onco.cc/trials/nct07729917/), [QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors](https://onco.cc/trials/nct06892925/), [QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer](https://onco.cc/trials/nct07733115/), [ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort](https://onco.cc/trials/roar/), [RUGB](https://onco.cc/trials/rugb/), [Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07701122/), [Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer](https://onco.cc/trials/nct06274879/), [SAFIR-ABC10](https://onco.cc/trials/safir-abc10/), [Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07025174/), [SEVILLA](https://onco.cc/trials/sevilla/), [Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.](https://onco.cc/trials/nct07654530/), [Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct07831993/), [Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations](https://onco.cc/trials/nct07598318/), [Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)](https://onco.cc/trials/nct06048133/), [Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors](https://onco.cc/trials/nct07726446/), [Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation](https://onco.cc/trials/nct06531291/), [SWOG S0809](https://onco.cc/trials/swog-s0809/), [SWOG S1815](https://onco.cc/trials/swog-s1815/), [Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA](https://onco.cc/trials/nct04183712/), [TESLA RCT](https://onco.cc/trials/tesla-rct/), [Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer](https://onco.cc/trials/nct04941287/), [Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers](https://onco.cc/trials/nct07437287/), [Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies](https://onco.cc/trials/nct04068194/), [The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma](https://onco.cc/trials/nct06355427/), [The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma](https://onco.cc/trials/nct07514533/), [The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer](https://onco.cc/trials/nct07160283/), [The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer](https://onco.cc/trials/nct05422690/), [The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers](https://onco.cc/trials/nct04781192/), [The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors](https://onco.cc/trials/nct07109167/), [TOPAZ-1](https://onco.cc/trials/topaz-1/), [Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer](https://onco.cc/trials/nct06717464/), [TRAP-BTC](https://onco.cc/trials/trap-btc/), [Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy](https://onco.cc/trials/nct07506057/), [Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients](https://onco.cc/trials/nct07062263/), [Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer](https://onco.cc/trials/nct07129018/), [TreeTopp](https://onco.cc/trials/treetopp/), [Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels](https://onco.cc/trials/nct07282912/), [Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct07146646/), [Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers](https://onco.cc/trials/nct06135896/), [Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer](https://onco.cc/trials/nct07267078/), [Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies](https://onco.cc/trials/nct07472933/), [Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers](https://onco.cc/trials/nct07723534/)

---
JSON: https://onco.cc/api/v1/entities/gallbladder-cancer-in-biliary-trials.json